PWMG
CRSP icon

Private Wealth Management Group’s CRISPR Therapeutics CRSP Stock Holding History

Private Wealth Management Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$546 Hold
10
– – ﹤0.01% 1403
2026
Q1 		$476 Hold
10
– – ﹤0.01% 1378
2025
Q4 		$525 Hold
10
– – ﹤0.01% 1398
2025
Q3 		$649 Hold
10
– – ﹤0.01% 1382
2025
Q2 		$487 Hold
10
– – ﹤0.01% 1425
2025
Q1 		$341 Hold
10
– – ﹤0.01% 1433
2024
Q4 		$394 Sell
10
-42
-81% -$1.98K ﹤0.01% 1465
2024
Q3 		$2.44K Buy
52
+42
+420% +$2.13K ﹤0.01% 987
2024
Q2 		$541 Sell
10
-14
-58% -$810 ﹤0.01% 1430
2024
Q1 		$1.64K Hold
24
– – ﹤0.01% 1064
2023
Q4 		$1.5K Buy
+24
New +$1.33K ﹤0.01% 1101

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Private Wealth Management Group's CRSP Position: Q2 2026 in Review

Private Wealth Management Group held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 10 shares worth $546. The position accounts for ﹤0.01% of the portfolio, ranked #1403.

Private Wealth Management Group first reported a position in CRSP in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.44K in Q3 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Private Wealth Management Group held 10 shares of CRISPR Therapeutics worth $546 as of Q2 2026.
  • Private Wealth Management Group left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Private Wealth Management Group's portfolio in Q2 2026, its #1403 holding.
  • Private Wealth Management Group first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Private Wealth Management Group's CRISPR Therapeutics position peaked at $2.44K in Q3 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Private Wealth Management Group's 13F filing for Q2 2026, filed 27 Jul 2026.